Does the media prefer ACAD or SMMT?

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.36 beat ACADIA Pharmaceuticals' score of -0.16 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Summit Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BBIO or ACAD?

In the previous week, BridgeBio Pharma had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 11 mentions for ACADIA Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.49 beat ACADIA Pharmaceuticals' score of -0.16 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor HALO or ACAD?

In the previous week, Halozyme Therapeutics had 14 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 11 mentions for ACADIA Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.64 beat ACADIA Pharmaceuticals' score of -0.16 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer BMRN or ACAD?

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 6 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.16 beat ACADIA Pharmaceuticals' score of -0.16 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

ACADIA Pharmaceuticals (ACAD) Competitors

$19.78 +0.20 (+1.02%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$19.84 +0.06 (+0.30%)

As of 10/9/2026 07:46 PM Eastern

Compare

ACAD vs. SMMT, BBIO, HALO, MDGL, and BMRN

Should you buy ACADIA Pharmaceuticals stock or one of its competitors? ACADIA Pharmaceuticals's main competitors and comparable companies include Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

ACADIA Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.18	$391M	$2.22	8.91
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Summit Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Summit Therapeutics	N/A	-168.94%	-141.92%

ACADIA Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.36 beat ACADIA Pharmaceuticals' score of -0.16 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Summit Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals presently has a consensus target price of $32.71, indicating a potential upside of 65.37%. Summit Therapeutics has a consensus target price of $28.61, indicating a potential upside of 62.64%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Summit Therapeutics on 13 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

In the previous week, BridgeBio Pharma had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 11 mentions for ACADIA Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.49 beat ACADIA Pharmaceuticals' score of -0.16 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

BridgeBio Pharma currently has a consensus target price of $105.42, suggesting a potential upside of 61.32%. ACADIA Pharmaceuticals has a consensus target price of $32.71, suggesting a potential upside of 65.37%. Given ACADIA Pharmaceuticals' higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

ACADIA Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.44	-$724.93M	-$3.57	N/A
ACADIA Pharmaceuticals	$1.07B	3.18	$391M	$2.22	8.91

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to BridgeBio Pharma's net margin of -97.03%. ACADIA Pharmaceuticals' return on equity of 9.03% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Summary

ACADIA Pharmaceuticals beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

In the previous week, Halozyme Therapeutics had 14 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 11 mentions for ACADIA Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.64 beat ACADIA Pharmaceuticals' score of -0.16 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has lower revenue, but higher earnings than Halozyme Therapeutics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.97	$316.89M	$3.35	32.96
ACADIA Pharmaceuticals	$1.07B	3.18	$391M	$2.22	8.91

Halozyme Therapeutics presently has a consensus target price of $94.00, indicating a potential downside of 14.87%. ACADIA Pharmaceuticals has a consensus target price of $32.71, indicating a potential upside of 65.37%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Halozyme Therapeutics' net margin of 24.86%. Halozyme Therapeutics' return on equity of 260.98% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Summary

Halozyme Therapeutics beats ACADIA Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Madrigal Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

ACADIA Pharmaceuticals presently has a consensus price target of $32.71, indicating a potential upside of 65.37%. Madrigal Pharmaceuticals has a consensus price target of $710.20, indicating a potential upside of 50.55%. Given ACADIA Pharmaceuticals' higher probable upside, equities analysts plainly believe ACADIA Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

ACADIA Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its share price is 204% less volatile than the broader market.

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Madrigal Pharmaceuticals' net margin of -25.32%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 6 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.25 beat ACADIA Pharmaceuticals' score of -0.16 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.18	$391M	$2.22	8.91
Madrigal Pharmaceuticals	$958.40M	11.37	-$288.28M	-$12.89	N/A

Summary

ACADIA Pharmaceuticals beats Madrigal Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

BioMarin Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

BioMarin Pharmaceutical presently has a consensus price target of $87.82, suggesting a potential upside of 60.28%. ACADIA Pharmaceuticals has a consensus price target of $32.71, suggesting a potential upside of 65.37%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.65
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

ACADIA Pharmaceuticals has a net margin of 33.42% compared to BioMarin Pharmaceutical's net margin of 2.14%. ACADIA Pharmaceuticals' return on equity of 9.03% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 6 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.16 beat ACADIA Pharmaceuticals' score of -0.16 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has lower revenue, but higher earnings than BioMarin Pharmaceutical. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.29	$348.90M	$0.37	148.08
ACADIA Pharmaceuticals	$1.07B	3.18	$391M	$2.22	8.91

Summary

ACADIA Pharmaceuticals beats BioMarin Pharmaceutical on 10 of the 16 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACAD vs. The Competition

Export

Metric	ACADIA Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.37B	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	8.91	13.62	275.30	26.16
Price / Sales	3.18	1,234.33	635.97	107.53
Price / Cash	22.07	116.56	76.38	53.09
Price / Book	2.73	17.17	11.22	6.33
Net Income	$391M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-0.85%	-1.34%	-0.89%	-1.40%
1 Month Performance	-28.70%	-8.45%	-4.42%	-3.47%
1 Year Performance	-1.40%	14.02%	7.03%	1.18%

ACADIA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACAD ACADIA Pharmaceuticals	4.7258 of 5 stars	$19.78 +1.0%	$32.71 +65.4%	-4.1%	$3.37B	$1.07B	8.91	798	Analyst Forecast
SMMT Summit Therapeutics	2.5958 of 5 stars	$17.27 +3.1%	$28.61 +65.6%	-22.3%	$13.37B	N/A	N/A	265	Positive News
BBIO BridgeBio Pharma	3.7566 of 5 stars	$66.14 -1.7%	$102.61 +55.1%	+19.3%	$13.15B	$502.08M	N/A	839	Analyst Forecast
HALO Halozyme Therapeutics	3.454 of 5 stars	$108.31 -1.4%	$91.20 -15.8%	+69.6%	$12.47B	$1.40B	32.33	423	Trending News Analyst Forecast Insider Trade
MDGL Madrigal Pharmaceuticals	3.1748 of 5 stars	$493.62 -1.2%	$710.20 +43.9%	+10.1%	$11.54B	$1.28B	N/A	915

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACAD) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. SMMT, BBIO, HALO, MDGL, and BMRN

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Summary

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does ACADIA Pharmaceuticals compare to Halozyme Therapeutics?

Summary

How does ACADIA Pharmaceuticals compare to Madrigal Pharmaceuticals?

Summary

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. SMMT, BBIO, HALO, MDGL, and BMRN

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Which has better valuation and earnings, ACAD or SMMT?

Is ACAD or SMMT more profitable?

Which has more volatility & risk, ACAD or SMMT?

Does the media prefer ACAD or SMMT?

Do analysts rate ACAD or SMMT?

Do insiders and institutionals have more ownership in ACAD or SMMT?

Summary

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Does the media favor BBIO or ACAD?

Which has more risk and volatility, BBIO or ACAD?

Do analysts rate BBIO or ACAD?

Which has better earnings and valuation, BBIO or ACAD?

Do institutionals & insiders believe in BBIO or ACAD?

Is BBIO or ACAD more profitable?

Summary

How does ACADIA Pharmaceuticals compare to Halozyme Therapeutics?

Does the media favor HALO or ACAD?

Do insiders and institutionals have more ownership in HALO or ACAD?

Which has higher valuation & earnings, HALO or ACAD?

Do analysts recommend HALO or ACAD?

Which has more risk & volatility, HALO or ACAD?

Is HALO or ACAD more profitable?

Summary

How does ACADIA Pharmaceuticals compare to Madrigal Pharmaceuticals?

Do analysts recommend ACAD or MDGL?

Which has more risk and volatility, ACAD or MDGL?

Do insiders & institutionals have more ownership in ACAD or MDGL?

Is ACAD or MDGL more profitable?

Does the media prefer ACAD or MDGL?

Which has higher earnings and valuation, ACAD or MDGL?

Summary

How does ACADIA Pharmaceuticals compare to BioMarin Pharmaceutical?

Which has more risk & volatility, BMRN or ACAD?

Do analysts recommend BMRN or ACAD?

Is BMRN or ACAD more profitable?

Does the media prefer BMRN or ACAD?

Do insiders and institutionals hold more shares of BMRN or ACAD?

Which has preferable valuation & earnings, BMRN or ACAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools